News
Ampersand Health is proud to announce its selection for the NHS Innovation Accelerator (NIA), a prestigious three-year programme that supports the scaling of proven healthcare innovations across the NHS. Recognised by the Financial Times as one of the world’s leading healthcare accelerators, the NIA provides a platform for impactful solutions to expand their reach and benefit more patients.
The programme aims to address pressing challenges within the NHS by facilitating the adoption of innovations that have already demonstrated significant improvements in patient outcomes and healthcare efficiency. Many of the solutions within the accelerator, including Ampersand Health’s offerings, have shown measurable success—such as reducing A&E visits by approximately 90% and clinic burdens by around 40% in other long-term conditions.
Ampersand Health is particularly committed to improving care for individuals living with immune-mediated conditions, including Crohn’s disease, ulcerative colitis, arthritis, psoriasis, and multiple sclerosis. While these conditions may not always be classified as “national priorities,” they affect over six million people in the UK and more than 600 million worldwide. Through participation in the NIA, Ampersand Health aims to champion high-quality, holistic healthcare solutions that enhance quality of life for these individuals.
This opportunity enables Ampersand Health to collaborate closely with NHS England, the Department of Health and Social Care, and leaders across the third sector to drive meaningful change. By scaling effective digital health interventions, the company remains dedicated to advancing patient-centred care and ensuring that individuals with immune-mediated conditions receive the support they deserve.
–
Image credit @NHS Innovation Accelerator
